Cardiff Oncology (CRDF) Competitors $2.32 +0.06 (+2.65%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.34 +0.02 (+0.86%) As of 08/22/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF vs. ABUS, KALV, KURA, BCAX, TSHA, VIR, TERN, RLAY, SIGA, and ORGOShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Bicara Therapeutics (BCAX), Taysha Gene Therapies (TSHA), Vir Biotechnology (VIR), Terns Pharmaceuticals (TERN), Relay Therapeutics (RLAY), Siga Technologies (SIGA), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Its Competitors Arbutus Biopharma KalVista Pharmaceuticals Kura Oncology Bicara Therapeutics Taysha Gene Therapies Vir Biotechnology Terns Pharmaceuticals Relay Therapeutics Siga Technologies Organogenesis Arbutus Biopharma (NASDAQ:ABUS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do analysts prefer ABUS or CRDF? Arbutus Biopharma presently has a consensus price target of $5.50, suggesting a potential upside of 53.20%. Cardiff Oncology has a consensus price target of $10.10, suggesting a potential upside of 335.34%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility & risk, ABUS or CRDF? Arbutus Biopharma has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Which has higher valuation and earnings, ABUS or CRDF? Cardiff Oncology has lower revenue, but higher earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.17M111.54-$69.92M-$0.29-12.38Cardiff Oncology$545K283.19-$45.43M-$0.87-2.67 Is ABUS or CRDF more profitable? Arbutus Biopharma has a net margin of -352.24% compared to Cardiff Oncology's net margin of -9,344.14%. Arbutus Biopharma's return on equity of -59.28% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-352.24% -59.28% -44.11% Cardiff Oncology -9,344.14%-77.94%-63.65% Do insiders and institutionals hold more shares of ABUS or CRDF? 43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to ABUS or CRDF? In the previous week, Arbutus Biopharma had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 2 mentions for Arbutus Biopharma and 0 mentions for Cardiff Oncology. Arbutus Biopharma's average media sentiment score of 1.23 beat Cardiff Oncology's score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Overall Sentiment Arbutus Biopharma Positive Cardiff Oncology Neutral SummaryArbutus Biopharma beats Cardiff Oncology on 10 of the 16 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.35M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-2.6720.8831.1026.05Price / Sales283.19342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book2.648.129.536.61Net Income-$45.43M-$54.72M$3.26B$265.56M7 Day Performance-4.92%2.63%2.10%1.97%1 Month Performance-45.92%2.78%2.81%-0.36%1 Year Performance-2.93%11.01%30.56%19.03% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.6378 of 5 stars$2.32+2.7%$10.10+335.3%+1.3%$150.35M$545K-2.6720ABUSArbutus Biopharma2.7782 of 5 stars$3.38+0.3%$5.50+62.7%-5.8%$645.07M$6.17M-11.6690News CoveragePositive NewsKALVKalVista Pharmaceuticals4.0422 of 5 stars$13.34+3.6%$26.29+97.0%+8.0%$643.40MN/A-3.62100KURAKura Oncology3.9546 of 5 stars$7.48+1.9%$24.10+222.2%-61.2%$637.09M$53.88M-3.31130BCAXBicara Therapeutics1.67 of 5 stars$11.47-1.5%$31.86+177.8%N/A$635.11MN/A-3.6232Analyst ForecastTSHATaysha Gene Therapies3.4165 of 5 stars$2.93-0.3%$8.29+182.8%+33.9%$631.10M$8.33M-8.62180VIRVir Biotechnology3.437 of 5 stars$4.48-0.9%$30.25+575.2%-45.0%$627.90M$74.21M-1.12580Positive NewsTERNTerns Pharmaceuticals3.7712 of 5 stars$6.76-4.1%$15.63+131.1%-11.9%$616.95MN/A-6.5040RLAYRelay Therapeutics2.0443 of 5 stars$3.47-2.0%$17.25+397.1%-46.8%$610.34M$10.01M-1.78330SIGASiga Technologies1.8797 of 5 stars$8.92+4.9%N/A-2.2%$608.65M$138.72M7.8940Options VolumeORGOOrganogenesis4.3015 of 5 stars$4.58-3.2%$7.50+63.8%+77.8%$600.04M$482.04M-32.71950Positive News Related Companies and Tools Related Companies ABUS Competitors KALV Competitors KURA Competitors BCAX Competitors TSHA Competitors VIR Competitors TERN Competitors RLAY Competitors SIGA Competitors ORGO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDF) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access